ERBB2 and breast cancer: The conducted meta-analysis showed that ever-use of OCs statistically non-significantly lowered the risk of HER2+BC: OR = 0.8810, 95% CI: 0.5977 to 1.2984, p = 0.522, with moderate heterogeneity: 62.94% (Figure 4).